Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ryanair Holdings plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Ryanair Holdings plc trades at $65.59 (market cap $32.49B). The key difference: Ryanair Holdings plc is far larger — about 7.2× ACADIA Pharmaceuticals Inc.'s market cap, and Ryanair Holdings plc pays a 1.49% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | RYAAY | |
|---|---|---|
Market Cap | $4.49B | $32.49B |
Sector | Health | Industrials |
52-Week High | $28.06 | $73.82 |
52-Week Low | $20.06 | $53.24 |
Enterprise Value | $3.69B | $30.15B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Ryanair Holdings (RYAAY) trades at $66.35, up 1.31% with bullish technical signals from moving averages. The company demonstrates strong fundamentals with a P/E of 14.42, net income margin of 13.98%, and consistent earnings beats. Recent traffic growth of 7% in June 2026 and improved family seating policy reflect operational strength. Cash flow from operations remains robust at $3.42B despite negative net cash flow of -$12M in 2025.
RYAAY presents a compelling investment case with analyst consensus favoring Buy (62.5%) and bullish technical indicators. The airline's debt-free balance sheet, 80% fuel hedge for 2027, and cost leadership provide competitive advantages. Key risks include rising operating costs, macroeconomic uncertainty, and potential regulatory pressures. The stock's current valuation appears reasonable given strong profitability metrics and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
